Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of its ...

Johnson & Johnson has agreed to buy biotechnology company Firefly Bio for $1 billion in cash in a deal that bolsters the ...

ADCs have become a core pillar of cancer treatment as increasingly sophisticated design is translating into stronger efficacy ...

Domestic bio companies have continued to show sluggish performance since the beginning of the year. While the bio sector, ...